The Epigenetic and Transcriptional Regulation of Tumor-Suppressor

Total Page:16

File Type:pdf, Size:1020Kb

The Epigenetic and Transcriptional Regulation of Tumor-Suppressor Dissertation submitted to the Combined Faculties for the Natural Sciences and for Mathematics of the Ruperto-Carola University of Heidelberg, Germany for the degree of Doctor of Natural Sciences presented by Diplom-Biology Olga Bogatyrova from Cherkassy, Ukraine Oral-examination: ................................................ Mutations in regulators of the epigenome and their effects on the DNA methylome Referees: Prof. Dr. Stefan Wiemann Prof. Dr. Christoph Plass Division of Epigenomics and Cancer Risk Factors Head of Division: Prof. Dr. Christoph Plass German Cancer Research Center (DKFZ) Heidelberg, Germany To all the people that helped me on the way… Contributions Parts of the introduction section of this thesis was prepared, based on the published review “Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer” by Plass et al. (2013) in the journal Nature Genetic Reviews, on which I am a co-author [1]. The text sections may therefore contain input from co-authors and figures in the respective sections are partially modified from the review, which is indicated in the caption and in accordance with the copyright policy of the publishers. The chapter 7 of this thesis was prepared for manuscript under the title “Epigenetic deregulation of miRNAs activates oncogenic pathways in prostate cancer” by Bogatyrova O*, Wuttig D.* et al. For the Results chapter 7, text phrases, selected tables, figures and the respective captions are based on the prepared manuscript and contain input from co-authors. Parts of the material and methods section concerning the Illumina HumanMethylation450 BeadChip assay and the Human Sentrix expression array analysis were conducted by the Genomics & Proteomics Core facility of the DKFZ. Data analysis and cluster performance of HumanMethylation450 BeadChip data was conducted with big help and supervision of Dr. Yassen Assenov. Declarations Declarations according to § 8 (3) b) and c) of the doctoral degree regulations: a) I hereby declare that I have written the submitted dissertation myself and in this process have used no other sources or materials than those expressly indicated, b) I hereby declare that I have not applied to be examined at any other institution, nor have I used the dissertation in this or any other form at any other institution as an examination paper, nor submitted it to any other faculty as a dissertation. Heidelberg, (Olga Bogatyrova) Table of contents |13 14 | Table of contents TABLE OF CONTENTS TABLE OF CONTENTS ................................................................................................................... 14 CHAPTER 1. SUMMARY .......................................................................................................... 18 Zusammenfassung .................................................................................................................... 20 CHAPTER2. LIST OF ABBREVIATIONS ................................................................................... 22 CHAPTER 3. INTRODUCTION ................................................................................................. 25 3.1. EPIGENETICS ....................................................................................................................... 25 3.1.1. Epigenetics and epigenetic alterations ............................................................................. 25 3.1.2. DNA modifications ........................................................................................................... 25 3.1.3. Histone modifications ....................................................................................................... 27 3.2. Major regulators of the epigenome ..................................................................................... 28 3.2.1 Complexes of epigenetic regulators in cancer .................................................................. 29 3.3. Non-coding RNAs ............................................................................................................... 29 3.4. Epigenetic alterations in cancer .......................................................................................... 33 3.4.1. Global DNA methylation alterations in cancer .................................................................. 34 3.4.2. Cancer drivers vs. passengers ........................................................................................ 37 3.4.3. Cancer driver mutations in the epigenome ....................................................................... 37 3.4.4. Integrative analysis of cancer genomes and epigenomes ................................................ 37 3.4.5. Disruption of ncRNAs in cancer ....................................................................................... 38 3.5. PanCancer studies ............................................................................................................. 41 3.6. Prostate cancer .................................................................................................................. 42 3.6.1. Deregulation of ncRNA in prostate cancer ....................................................................... 42 CHAPTER 4. AIMS OF THE THESIS ........................................................................................ 46 CHAPTER 5. MATERIAL AND METHODS ............................................................................... 48 5.1. General equipment, disposables and chemical substances ................................................ 48 5.2. Primers ............................................................................................................................... 48 5.3. Tissue samples ................................................................................................................... 48 5.4. Data sets ............................................................................................................................ 51 5.5. DNA methylation analysis ................................................................................................... 51 5.6. miRNA expression analysis ................................................................................................ 54 5.7. Data analysis ...................................................................................................................... 55 Table of contents |15 RESULTS .................................................................................................................................. 59 CHAPTER 6. Mutations in regulators of the epigenome and their effects on the DNA methylome ................................................................................................................................ 59 6.1. ALTERATIONS IN EPIGENETIC REGULATORS IN CANCER ........................................................... 61 6.1.1. Putative driver epigenetic regulators ................................................................................ 63 6.1.2. Alterations in complexes of epigenetic regulators in cancer ............................................. 69 6.2. Identification patterns/clusters of DNA methylation in cancer .............................................. 70 6.3. Correlative analysis of methylome data with defects in epigenetic regulators ..................... 75 6.4. Differently methylated regions in cancer ............................................................................. 75 6.5. Discussion of results and deliveribles ................................................................................ 75 CHAPTER 7. Global integrative analyses of deregulated miRNAs in prostate cancer ............... 81 7.1. Global deregulation of miRNA expression in early-onset prostate cancer (EO-PCA) .......... 82 7.2. Genetic and epigenetic alterations associated with miRNA downregulation in EO-PCA .... 89 7.3. Genetic and epigenetic aberrations associated with miRNA upregulation in EO-PCA........ 89 7.4. Translocations associated with miRNAs deregulation in EO-PCA ...................................... 89 7.5. Tumor-suppressive and oncogenic miRNAs in EO-PCA ..................................................... 89 7.6. Expression profile of miRNAs in different groups of EO-PCA..............................................94 7.7. Promoter DNA-methylation associated with miRNA deregulation in LO-PCA ..................... 95 7.7.1. Validation of promoter DNA-methylation associated with miRNAs deregulation in PCA...95 7.7.2. Epigenetically regulated miRNAs activate key oncogenic pathways in PCA………………97 7.8. PTEN inactivation by miRNA in PCA ............................................................................... 100 7.9. miRNAs promoter DNA-methylation in cancer ................................................................. 100 7.10. Discussion of results ....................................................................................................... 101 CHAPTER 8. Mechanisms leading to deregulation of lncRNA in prostate cancer – an integrative analysis .............................................................................................................................. 104 8.1. Expression profile of lncRNAs in EO-PCA ........................................................................ 105 8.2. Genetic aberrations associated with lncRNA deregulation in EO-PCA .............................. 108 8.3. Promoter DNA-methylation associated with lncRNA deregulation in EO-PCA .................. 108 8.4. Correlation
Recommended publications
  • Aberrant Methylation Underlies Insulin Gene Expression in Human Insulinoma
    ARTICLE https://doi.org/10.1038/s41467-020-18839-1 OPEN Aberrant methylation underlies insulin gene expression in human insulinoma Esra Karakose1,6, Huan Wang 2,6, William Inabnet1, Rajesh V. Thakker 3, Steven Libutti4, Gustavo Fernandez-Ranvier 1, Hyunsuk Suh1, Mark Stevenson 3, Yayoi Kinoshita1, Michael Donovan1, Yevgeniy Antipin1,2, Yan Li5, Xiaoxiao Liu 5, Fulai Jin 5, Peng Wang 1, Andrew Uzilov 1,2, ✉ Carmen Argmann 1, Eric E. Schadt 1,2, Andrew F. Stewart 1,7 , Donald K. Scott 1,7 & Luca Lambertini 1,6 1234567890():,; Human insulinomas are rare, benign, slowly proliferating, insulin-producing beta cell tumors that provide a molecular “recipe” or “roadmap” for pathways that control human beta cell regeneration. An earlier study revealed abnormal methylation in the imprinted p15.5-p15.4 region of chromosome 11, known to be abnormally methylated in another disorder of expanded beta cell mass and function: the focal variant of congenital hyperinsulinism. Here, we compare deep DNA methylome sequencing on 19 human insulinomas, and five sets of normal beta cells. We find a remarkably consistent, abnormal methylation pattern in insu- linomas. The findings suggest that abnormal insulin (INS) promoter methylation and altered transcription factor expression create alternative drivers of INS expression, replacing cano- nical PDX1-driven beta cell specification with a pathological, looping, distal enhancer-based form of transcriptional regulation. Finally, NFaT transcription factors, rather than the cano- nical PDX1 enhancer complex, are predicted to drive INS transactivation. 1 From the Diabetes Obesity and Metabolism Institute, The Department of Surgery, The Department of Pathology, The Department of Genetics and Genomics Sciences and The Institute for Genomics and Multiscale Biology, The Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
    [Show full text]
  • The Human Y Chromosome's Azoospermia Factor B (Azfb) Region
    18 ORIGINAL ARTICLE J Med Genet: first published as 10.1136/jmg.40.1.18 on 1 January 2003. Downloaded from The human Y chromosome’s azoospermia factor b (AZFb) region: sequence, structure, and deletion analysis in infertile men A Ferlin, E Moro, A Rossi, B Dallapiccola, C Foresta ............................................................................................................................. J Med Genet 2003;40:18–24 See end of article for authors’ affiliations Microdeletions of the Y chromosome long arm are the most common mutations in infertile males, where ....................... they involve one or more “azoospermia factors” (AZFa, b, and c). Understanding of the AZF structure and gene content and mapping of the deletion breakpoints in infertile men are still incomplete. We Correspondence to: Professor C Foresta, have assembled a complete 4.3 Mb map of AZFb and surrounding regions by means of 38 BAC University of Padova, clones. The proximal part of AZFb consists of large repeated sequences organised in palindromes, but Department of Medical and most of it is single copy sequence. A number of known and novel genes and gene families map in this Surgical Sciences, Clinica interval, and most of them are testis specific or have testis specific transcripts. STS mapping allowed us Medica 3, Via Ospedale to identify four severely infertile subjects with a deletion in AZFb with similar breakpoints, therefore 105, 35128 Padova, Italy; [email protected] suggesting a common deletion mechanism. This deletion includes at least five single copy genes and two duplicated genes, but does not remove the historical AZFb candidate gene RBMY1. These data Revised version received suggest that other genes in AZFb may have important roles in spermatogenesis.
    [Show full text]
  • Focus on the Small Heat Shock Protein HSPB1 Autofagie in De Erfelij
    Faculteit Faculteit Farmaceutische, Biomedische en Diergeneeskundige wetenschappen Biochemie en Biotechnologie Autophagy in inherited peripheral neuropathies: Focus on the small heat shock protein HSPB1 Autofagie in de erfelijke perifere neuropathieën: Focus op de kleine heat shock proteïne HSPB1 Proefschrift voorgelegd tot het behalen van de graad van Doctor in de Wetenschappen: Biochemie en Biotechnologie aan de Universiteit Antwerpen. te verdedigen door Mansour HAIDAR Promotor Prof. Dr. Vincent Timmerman Antwerpen, 2018 1 2 “Haud igitur redit ad Nihilum res ulla, sed omnes Discidio redeunt in corpora materiai” Lucretius, De Rerum Natura, Book I. 250 3 4 Members of the jury Chair Prof. Dr. Wim Vanden Berghe, PhD (UA, Antwerp, Belgium) Promotor Prof. Dr. Vincent Timmerman, PhD (UA, Antwerp, Belgium) Internal jury member Prof. Dr. Wim Martinet, PhD (UA, Antwerp, Belgium) External jury members Prof. Dr. Joy Irobi (UHasselt, Hasselt, Belgium) Prof. Dr. Maurizio D’Antonio (San Raffaele Institute, Milan, Italy) Prof. Dr. Ir. Winnok De Vos (UA, Antwerp, Belgium) 5 6 Table of Contents Summary/Samenvatting 9 Rationale and Aims 13 Introduction Chapter 1 Autophagy as an emerging common pathomechanism in inherited 15 peripheral neuropathies Chapter 2 Small heat shock proteins: Their role in proteostasis 79 and neurodegeneration Results Chapter 3 HSPB1 is required for Autophagy: Insights from CMT-causing mutations 103 Chapter 4 An interactomics study of HSPB1 wild-type and mutant links it to the 129 autophagy receptor P62 Discussion 179 List of abbreviations 195 Curriculum Vitae 199 Acknowledgements 203 7 8 Summary Inherited peripheral neuropathies (IPNs) are genetically heterogeneous disorders affecting mainly the peripheral nervous system and with over 1500 mutations in more than 80 affected genes discovered so far.
    [Show full text]
  • Research Article Characterization, Tissue Expression, and Imprinting Analysis of the Porcine CDKN1C and NAP1L4 Genes
    Hindawi Publishing Corporation Journal of Biomedicine and Biotechnology Volume 2012, Article ID 946527, 7 pages doi:10.1155/2012/946527 Research Article Characterization, Tissue Expression, and Imprinting Analysis of the Porcine CDKN1C and NAP1L4 Genes Shun Li,1 Juan Li,1 Jiawei Tian,1 Ranran Dong,1 Jin Wei,1 Xiaoyan Qiu,2 and Caode Jiang2 1 School of Life Science, Southwest University, Chongqing 400715, China 2 College of Animal Science and Technology, Southwest University, Chongqing 400715, China Correspondence should be addressed to Caode Jiang, [email protected] Received 4 August 2011; Revised 25 October 2011; Accepted 15 November 2011 Academic Editor: Andre Van Wijnen Copyright © 2012 Shun Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. CDKN1C and NAP1L4 in human CDKN1C/KCNQ1OT1 imprinted domain are two key candidate genes responsible for BWS (Beckwith-Wiedemann syndrome) and cancer. In order to increase understanding of these genes in pigs, their cDNAs are characterized in this paper. By the IMpRH panel, porcine CDKN1C and NAP1L4 genes were assigned to porcine chromosome 2, closely linked with IMpRH06175 and with LOD of 15.78 and 17.94, respectively. By real-time quantitative RT-PCR and polymorphism-based method, tissue and allelic expression of both genes were determined using F1 pigs of Rongchang and Landrace reciprocal crosses. The transcription levels of porcine CDKN1C and NAP1L4 were significantly higher in placenta than in other neonatal tissues (P<0.01) although both genes showed the highest expression levels in the lung and kidney of one- month pigs (P<0.01).
    [Show full text]
  • Supporting Information
    Supporting Information Edgar et al. 10.1073/pnas.1601895113 SI Methods (Actimetrics), and recordings were analyzed using LumiCycle Mice. Sample size was determined using the resource equation: Data Analysis software (Actimetrics). E (degrees of freedom in ANOVA) = (total number of exper- – Cell Cycle Analysis of Confluent Cell Monolayers. NIH 3T3, primary imental animals) (number of experimental groups), with −/− sample size adhering to the condition 10 < E < 20. For com- WT, and Bmal1 fibroblasts were sequentially transduced − − parison of MuHV-4 and HSV-1 infection in WT vs. Bmal1 / with lentiviral fluorescent ubiquitin-based cell cycle indicators mice at ZT7 (Fig. 2), the investigator did not know the genotype (FUCCI) mCherry::Cdt1 and amCyan::Geminin reporters (32). of the animals when conducting infections, bioluminescence Dual reporter-positive cells were selected by FACS (Influx Cell imaging, and quantification. For bioluminescence imaging, Sorter; BD Biosciences) and seeded onto 35-mm dishes for mice were injected intraperitoneally with endotoxin-free lucif- subsequent analysis. To confirm that expression of mCherry:: Cdt1 and amCyan::Geminin correspond to G1 (2n DNA con- erin (Promega E6552) using 2 mg total per mouse. Following < ≤ anesthesia with isofluorane, they were scanned with an IVIS tent) and S/G2 (2 n 4 DNA content) cell cycle phases, Lumina (Caliper Life Sciences), 15 min after luciferin admin- respectively, cells were stained with DNA dye DRAQ5 (abcam) and analyzed by flow cytometry (LSR-Fortessa; BD Biosci- istration. Signal intensity was quantified using Living Image ences). To examine dynamics of replicative activity under ex- software (Caliper Life Sciences), obtaining maximum radiance perimental confluent conditions, synchronized FUCCI reporter for designated regions of interest (photons per second per − − − monolayers were observed by time-lapse live cell imaging over square centimeter per Steradian: photons·s 1·cm 2·sr 1), relative 3 d (Nikon Eclipse Ti-E inverted epifluorescent microscope).
    [Show full text]
  • Snps) Distant from Xenobiotic Response Elements Can Modulate Aryl Hydrocarbon Receptor Function: SNP-Dependent CYP1A1 Induction S
    Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2018/07/06/dmd.118.082164.DC1 1521-009X/46/9/1372–1381$35.00 https://doi.org/10.1124/dmd.118.082164 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 46:1372–1381, September 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Single Nucleotide Polymorphisms (SNPs) Distant from Xenobiotic Response Elements Can Modulate Aryl Hydrocarbon Receptor Function: SNP-Dependent CYP1A1 Induction s Duan Liu, Sisi Qin, Balmiki Ray,1 Krishna R. Kalari, Liewei Wang, and Richard M. Weinshilboum Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics (D.L., S.Q., B.R., L.W., R.M.W.) and Division of Biomedical Statistics and Informatics, Department of Health Sciences Research (K.R.K.), Mayo Clinic, Rochester, Minnesota Received April 22, 2018; accepted June 28, 2018 ABSTRACT Downloaded from CYP1A1 expression can be upregulated by the ligand-activated aryl fashion. LCLs with the AA genotype displayed significantly higher hydrocarbon receptor (AHR). Based on prior observations with AHR-XRE binding and CYP1A1 mRNA expression after 3MC estrogen receptors and estrogen response elements, we tested treatment than did those with the GG genotype. Electrophoretic the hypothesis that single-nucleotide polymorphisms (SNPs) map- mobility shift assay (EMSA) showed that oligonucleotides with the ping hundreds of base pairs (bp) from xenobiotic response elements AA genotype displayed higher LCL nuclear extract binding after (XREs) might influence AHR binding and subsequent gene expres- 3MC treatment than did those with the GG genotype, and mass dmd.aspetjournals.org sion.
    [Show full text]
  • The Role of Y Chromosome Deletions in Male Infertility
    European Journal of Endocrinology (2000) 142 418–430 ISSN 0804-4643 INVITED REVIEW The role of Y chromosome deletions in male infertility Kun Ma, Con Mallidis and Shalender Bhasin Division of Endocrinology, Metabolism and Molecular Medicine, Department of Internal Medicine, Charles R Drew University of Medicine and Science, 1731 East 120th Street, Los Angeles, California 90050, USA (Correspondence should be addressed to K Ma; Email: [email protected]) Abstract Male infertility affects approximately 2–7% of couples around the world. Over one in ten men who seek help at infertility clinics are diagnosed as severely oligospermic or azoospermic. Recent extensive molecular studies have revealed that deletions in the azoospermia factor region of the long arm of the Y chromosome are associated with severe spermatogenic impairment (absent or severely reduced germ cell development). Genetic research into male infertility, in the last 7 years, has resulted in the isolation of a great number of genes or gene families on the Y chromosome, some of which are believed to influence spermatogenesis. European Journal of Endocrinology 142 418–430 Introduction of Infertility, with the objective of creating a standard protocol for the investigation of infertile couples. Normal Defective spermatogenesis is the result of a multitude of semen was classified as containing a sperm concentra- causes, such as diseases, malnutrition, endocrinological 6 tion of at least 20 × 10 /ml, of which more than 40% disorders, genetic defects or environmental hazards (1). are progressively motile, more than 60% are alive, and Genetic defects, such as mutations and chromosomal over 50% show normal morphology. In addition, the abnormalities, have been estimated to account for at 6 semen should contain no more than 1 × 10 /ml of white least 30% of male infertility (2).
    [Show full text]
  • A Genomic Atlas of Human Adrenal and Gonad Development [Version 2; Referees: 4 Approved] Ignacio Del Valle1, Federica Buonocore1, Andrew J
    Wellcome Open Research 2017, 2:25 Last updated: 08 NOV 2017 RESEARCH ARTICLE A genomic atlas of human adrenal and gonad development [version 2; referees: 4 approved] Ignacio del Valle1, Federica Buonocore1, Andrew J. Duncan1, Lin Lin1, Martino Barenco2, Rahul Parnaik1, Sonia Shah3,4, Mike Hubank5, Dianne Gerrelli2, John C. Achermann 1 1Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, London, UK 2Developmental Biology and Cancer, UCL Great Ormond Street Institute of Child Health, London, UK 3Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia 4Institute of Cardiovascular Science, University College London, London, UK 5The Centre for Molecular Pathology, Royal Marsden Hospital, Sutton, UK v2 First published: 07 Apr 2017, 2:25 (doi: 10.12688/wellcomeopenres.11253.1) Open Peer Review Latest published: 23 Oct 2017, 2:25 (doi: 10.12688/wellcomeopenres.11253.2) Referee Status: Abstract Background: In humans, the adrenal glands and gonads undergo distinct biological events between 6-10 weeks post conception (wpc), such as testis Invited Referees determination, the onset of steroidogenesis and primordial germ cell 1 2 3 4 development. However, relatively little is currently known about the genetic mechanisms underlying these processes. We therefore aimed to generate a detailed genomic atlas of adrenal and gonad development across these critical version 2 report report stages of human embryonic and fetal development. published Methods: RNA was extracted from 53 tissue samples between 6-10 wpc 23 Oct 2017 (adrenal, testis, ovary and control). Affymetrix array analysis was performed and differential gene expression was analysed using Bioconductor. A version 1 mathematical model was constructed to investigate time-series changes across published report report report report 07 Apr 2017 the dataset.
    [Show full text]
  • Partial Azfc Deletions and Duplications: Clinical Correlates in the Italian Population
    FLORE Repository istituzionale dell'Università degli Studi di Firenze Partial AZFc deletions and duplications: clinical correlates in the Italian population. Questa è la Versione finale referata (Post print/Accepted manuscript) della seguente pubblicazione: Original Citation: Partial AZFc deletions and duplications: clinical correlates in the Italian population / Giachini C; Laface I; Guarducci E; Balercia G; Forti G; Krausz C.. - In: HUMAN GENETICS. - ISSN 0340-6717. - STAMPA. - 124(2008), pp. 399-410. Availability: This version is available at: 2158/333113 since: 2019-11-07T18:24:55Z Terms of use: Open Access La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf) Publisher copyright claim: (Article begins on next page) 28 September 2021 Hum Genet (2008) 124:399–410 DOI 10.1007/s00439-008-0561-1 ORIGINAL INVESTIGATION Partial AZFc deletions and duplications: clinical correlates in the Italian population Claudia Giachini · Ilaria Laface · Elena Guarducci · Giancarlo Balercia · Gianni Forti · Csilla Krausz Received: 7 August 2008 / Accepted: 9 September 2008 / Published online: 21 September 2008 © Springer-Verlag 2008 Abstract The role of partial AZFc deletions of the Y potential methodological and selection biases were care- chromosome in spermatogenic impairment is currently fully avoided to detect the clinical signiWcance of partial debated. Recently, it was also reported that duplications of AZFc deletions and duplications. Our study provides strong the same region are associated with oligozoospermia in evidence that gr/gr deletion is a risk factor for impaired Han-Chinese men.
    [Show full text]
  • A Mutation in Histone H2B Represents a New Class of Oncogenic Driver
    Author Manuscript Published OnlineFirst on July 23, 2019; DOI: 10.1158/2159-8290.CD-19-0393 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. A Mutation in Histone H2B Represents A New Class Of Oncogenic Driver Richard L. Bennett1, Aditya Bele1, Eliza C. Small2, Christine M. Will2, Behnam Nabet3, Jon A. Oyer2, Xiaoxiao Huang1,9, Rajarshi P. Ghosh4, Adrian T. Grzybowski5, Tao Yu6, Qiao Zhang7, Alberto Riva8, Tanmay P. Lele7, George C. Schatz9, Neil L. Kelleher9 Alexander J. Ruthenburg5, Jan Liphardt4 and Jonathan D. Licht1 * 1 Division of Hematology/Oncology, University of Florida Health Cancer Center, Gainesville, FL 2 Division of Hematology/Oncology, Northwestern University 3 Department of Cancer Biology, Dana Farber Cancer Institute and Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School 4 Department of Bioengineering, Stanford University 5 Department of Molecular Genetics and Cell Biology, The University of Chicago 6 Department of Chemistry, Tennessee Technological University 7 Department of Chemical Engineering, University of Florida 8 Bioinformatics Core, Interdisciplinary Center for Biotechnology Research, University of Florida 9 Department of Chemistry, Northwestern University, Evanston IL 60208 Running title: Histone mutations in cancer *Corresponding Author: Jonathan D. Licht, MD The University of Florida Health Cancer Center Cancer and Genetics Research Complex, Suite 145 2033 Mowry Road Gainesville, FL 32610 352-273-8143 [email protected] Disclosures: The authors have no conflicts of interest to declare Downloaded from cancerdiscovery.aacrjournals.org on September 27, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on July 23, 2019; DOI: 10.1158/2159-8290.CD-19-0393 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • Letters to the Editor J Med Genet: First Published As 10.1136/Jmg.37.3.231 on 1 March 2000
    210 Letters Letters to the Editor J Med Genet: first published as 10.1136/jmg.37.3.231 on 1 March 2000. Downloaded from J Med Genet 2000;37:210–212 No evidence of germline PTEN three reasons: somatic mutations have been found in PTEN in prostate tumours; germline mutations in Cowden mutations in familial prostate cancer disease produce a phenotype (although with no evidence of an associated susceptibility to prostate cancer); and PTEN deficient mice exhibit prostate abnormalities. We have therefore screened the Cancer Research Campaign/British EDITOR—Prostate cancer is the second most common Prostate Group (CRC/BPG) UK Familial Prostate Cancer cause of male cancer mortality in the UK.1 Current indica- Study samples for evidence of PTEN mutations. tions are that like many common cancers, prostate cancer The CRC/BPG UK Familial Prostate Cancer Study has has an inherited component.2 Segregation analysis has led collected lymphocyte DNA from 188 subjects from 50 to the proposed model of at least one highly penetrant, prostate cancer families. These families were chosen dominant gene (with an estimated 88% penetrance for because each contained three or more cases of prostate prostate cancer by the age of 85 in the highly susceptible cancer at any age or related sib pairs where at least one man population). Such a gene or genes would account for an was less than 67 (original criterion was 65) years old at estimated 43% of cases diagnosed at less than 55 years.2 diagnosis. In fact, the majority of the clusters consist of One prostate cancer susceptibility locus (HPC1) has been aVected sib pairs, with DNA often only available from reported on 1q24-253 and confirmed by Cooney et al4 and cases.
    [Show full text]
  • Mclean, Chelsea.Pdf
    COMPUTATIONAL PREDICTION AND EXPERIMENTAL VALIDATION OF NOVEL MOUSE IMPRINTED GENES A Dissertation Presented to the Faculty of the Graduate School of Cornell University In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy by Chelsea Marie McLean August 2009 © 2009 Chelsea Marie McLean COMPUTATIONAL PREDICTION AND EXPERIMENTAL VALIDATION OF NOVEL MOUSE IMPRINTED GENES Chelsea Marie McLean, Ph.D. Cornell University 2009 Epigenetic modifications, including DNA methylation and covalent modifications to histone tails, are major contributors to the regulation of gene expression. These changes are reversible, yet can be stably inherited, and may last for multiple generations without change to the underlying DNA sequence. Genomic imprinting results in expression from one of the two parental alleles and is one example of epigenetic control of gene expression. So far, 60 to 100 imprinted genes have been identified in the human and mouse genomes, respectively. Identification of additional imprinted genes has become increasingly important with the realization that imprinting defects are associated with complex disorders ranging from obesity to diabetes and behavioral disorders. Despite the importance imprinted genes play in human health, few studies have undertaken genome-wide searches for new imprinted genes. These have used empirical approaches, with some success. However, computational prediction of novel imprinted genes has recently come to the forefront. I have developed generalized linear models using data on a variety of sequence and epigenetic features within a training set of known imprinted genes. The resulting models were used to predict novel imprinted genes in the mouse genome. After imposing a stringency threshold, I compiled an initial candidate list of 155 genes.
    [Show full text]